Targeted Therapy-induced Facial Skin Toxicities: Impact on Quality of Life in Cancer Patients

Overview

Journal Asia Pac J Oncol Nurs

Publisher Elsevier

Date 2018 Apr 3

PMID 29607377

Citations 4

Authors

Kaori Yagasaki

Hiroko Komatsu

Kenzo Soejima

Katsuhiko Naoki

Ichiro Kawada

Hiroyuki Yasuda

Yasuo Hamamoto

Affiliations

Soon will be listed here.

Abstract

Objective: Targeted therapy-induced facial skin toxicities may reduce overall quality of life (QoL) in cancer patients. We investigated whether facial skin toxicities affect QoL and attempted to identify factors related to QoL in patients with advanced/recurrent cancer.

Methods: We performed a cross-sectional study in 34 outpatients with advanced/recurrent cancer showing targeted therapy-induced facial skin toxicities in Japan between November 2016 and February 2017. For measurement, we used the Kessler Psychological Distress Scale (K6), Mental Adjustment to Cancer (MAC) Scale, and Dermatology Life Quality Index (DLQI). Data were analyzed using Spearman's rank correlation coefficient.

Results: Mean DLQI score in 34 patients was 4.59 (standard deviation ± 4.70), which was interpreted as a small effect on a patient's life. Acneiform rash was the most common skin condition noted, followed by xerosis, pruritus, and erythema. Analysis of DLQI scores revealed that symptoms and feelings was the domain most commonly affected among different domains constituting the DLQI. MAC analysis revealed that the fighting spirit score was the highest among MAC scales. We found that age, K6, and fatalism construct in MAC were significantly correlated with total DLQI scores (age: Spearman's ρ= -0.48, = 0.004; K6: ρ= 0.58, < 0.001; fatalism; ρ= -0.39, = 0.025).

Conclusions: This is the first study investigating targeted therapy-induced facial skin toxicities in cancer patients. Our results suggest potential negative effects of facial skin toxicities on overall QoL in patients with advanced/recurrent cancer in middle and early old age.

Citing Articles

The Impact of Dermatologic Adverse Events on the Quality of Life of Oncology Patients: A Review of the Literature.

Belzer A, Pach J, Valido K, Leventhal J Am J Clin Dermatol. 2024; 25(3):435-445.

PMID: 38366030 DOI: 10.1007/s40257-024-00847-2.

Home-based multidisciplinary interventions on skin adverse reactions in EGFR-TKI-treated patients with lung cancer: a protocol for a randomised controlled trial.

Du R, Yang H, Zhou H, Ma L, Getu M, Chen C BMJ Open. 2022; 12(11):e063921.

PMID: 36442902 PMC: 9710339. DOI: 10.1136/bmjopen-2022-063921.

Du R, Wang X, Zhou H, Ma L, Larcher L, Chen C Support Care Cancer. 2022; 30(12):9889-9899.

PMID: 36400979 DOI: 10.1007/s00520-022-07451-2.

The relationship between medication literacy and skin adverse reactions in non-small-cell lung cancer patients undergoing targeted EGFR-TKI therapy.

Du R, Yang H, Zhou H, Ma L, Getu M, Chen C BMC Cancer. 2022; 22(1):491.

PMID: 35505288 PMC: 9066960. DOI: 10.1186/s12885-022-09599-w.

References

Watson M, Greer S, Young J, Inayat Q, Burgess C, Robertson B . Development of a questionnaire measure of adjustment to cancer: the MAC scale. Psychol Med. 1988; 18(1):203-9. DOI: 10.1017/s0033291700002026. View

Finlay A, Khan G . Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994; 19(3):210-6. DOI: 10.1111/j.1365-2230.1994.tb01167.x. View

Holm J, Agner T, Clausen M, Thomsen S . Quality of life and disease severity in patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2016; 30(10):1760-1767. DOI: 10.1111/jdv.13689. View

Czerw A, Religioni U, Deptala A, Walewska-Zielecka B . Assessment of pain, acceptance of illness, adjustment to life with cancer, and coping strategies in colorectal cancer patients. Prz Gastroenterol. 2016; 11(2):96-103. PMC: 4916231. DOI: 10.5114/pg.2015.52561. View

Golchai J, Khani S, Heidarzadeh A, Eshkevari S, Alizade N, Eftekhari H . Comparison of anxiety and depression in patients with acne vulgaris and healthy individuals. Indian J Dermatol. 2011; 55(4):352-4. PMC: 3051295. DOI: 10.4103/0019-5154.74539. View

Czerw A, Religioni U, Deptala A . Adjustment to Life with Lung Cancer. Adv Clin Exp Med. 2016; 25(4):733-40. DOI: 10.17219/acem/61014. View

Vilar G, Dos Santos L, Sobral Filho J . Quality of life, self-esteem and psychosocial factors in adolescents with acne vulgaris. An Bras Dermatol. 2015; 90(5):622-9. PMC: 4631226. DOI: 10.1590/abd1806-4841.201533726. View

Lacouture M, Anadkat M, Bensadoun R, Bryce J, Chan A, Epstein J . Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011; 19(8):1079-95. PMC: 3128700. DOI: 10.1007/s00520-011-1197-6. View

Reyes-Habito C, Roh E . Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: Part II. Targeted therapy. J Am Acad Dermatol. 2014; 71(2):217.e1-217.e11. DOI: 10.1016/j.jaad.2014.04.013. View

10.

Pinto C, Di Fabio F, Rosati G, Lolli I, Ruggeri E, Ciuffreda L . Observational study on quality of life, safety, and effectiveness of first-line cetuximab plus chemotherapy in KRAS wild-type metastatic colorectal cancer patients: the ObservEr Study. Cancer Med. 2016; 5(11):3272-3281. PMC: 5119983. DOI: 10.1002/cam4.888. View

11.

Furukawa T, Kessler R, Slade T, Andrews G . The performance of the K6 and K10 screening scales for psychological distress in the Australian National Survey of Mental Health and Well-Being. Psychol Med. 2003; 33(2):357-62. DOI: 10.1017/s0033291702006700. View

12.

Coleman S, Kovtun I, Nguyen P, Pittelkow M, Jatoi A . A qualitative study of the ramifications of rash from epidermal growth factor receptor (EGFR) inhibitors. Psychooncology. 2010; 20(11):1246-9. PMC: 4556526. DOI: 10.1002/pon.1847. View

13.

Tischer B, Huber R, Kraemer M, Lacouture M . Dermatologic events from EGFR inhibitors: the issue of the missing patient voice. Support Care Cancer. 2016; 25(2):651-660. PMC: 5196015. DOI: 10.1007/s00520-016-3419-4. View

14.

Kessler R, Barker P, Colpe L, Epstein J, Gfroerer J, Hiripi E . Screening for serious mental illness in the general population. Arch Gen Psychiatry. 2003; 60(2):184-9. DOI: 10.1001/archpsyc.60.2.184. View

15.

Takahashi N, Suzukamo Y, Nakamura M, Miyachi Y, Green J, Ohya Y . Japanese version of the Dermatology Life Quality Index: validity and reliability in patients with acne. Health Qual Life Outcomes. 2006; 4:46. PMC: 1557837. DOI: 10.1186/1477-7525-4-46. View

16.

Clabbers J, Boers-Doets C, Gelderblom H, Stijnen T, Lacouture M, van der Hoeven K . Xerosis and pruritus as major EGFRI-associated adverse events. Support Care Cancer. 2015; 24(2):513-521. PMC: 4689742. DOI: 10.1007/s00520-015-2781-y. View

17.

Akechi T, Kugaya A, Okamura H, Nishiwaki Y, Yamawaki S, Uchitomi Y . Psychometric properties of the Japanese version of the Mental Adjustment to Cancer (MAC) scale. Psychooncology. 2000; 9(5):395-401. DOI: 10.1002/1099-1611(200009/10)9:5<395::aid-pon472>3.0.co;2-o. View

18.

Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni P . Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res. 2007; 13(13):3913-21. DOI: 10.1158/1078-0432.CCR-06-2610. View

19.

Rosen A, Case E, Dusza S, Balagula Y, Gordon J, West D . Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. Am J Clin Dermatol. 2013; 14(4):327-33. DOI: 10.1007/s40257-013-0021-0. View

20.

Joshi S, Ortiz S, Witherspoon J, Rademaker A, West D, Anderson R . Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer. 2010; 116(16):3916-23. DOI: 10.1002/cncr.25090. View